Chronic News and Research

RSS

Researchers identify gene associated with susceptibility to chronic pain caused by nerve injury

Researchers at the Hebrew University of Jerusalem and elsewhere have succeeded in identifying for the first time a gene associated with susceptibility to chronic pain caused by nerve injury in humans, signaling a significant step toward better understanding and treating of the condition.

6 Aug 2010

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

YM BioSciences Inc., announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients.

5 Aug 2010

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

5 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

BioCryst second-quarter total revenues increase to $7.6 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

New studies question wide-spread hypothesis that CCSVI contribute to development of MS

Researchers at Umeå University in Sweden have performed a study that indicates that neither blood flow nor the flow of spinal fluid in the brain contribute to the development of multiple sclerosis, MS. The findings run directly counter to a much-discussed and widely spread Italian theory.

5 Aug 2010

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients in the United States.

5 Aug 2010

EBRI publishes detailed summary of consumer-driven health plans

The nonpartisan Employee Benefit Research Institute today published a detailed summary of what is known about consumer-driven health plans, a relatively new option for paying for medical expenses that first began to appear nearly a decade ago.

5 Aug 2010

Project for improving nurses' assessment skills to detect and alleviate delirium symptoms

In the future, nurses may more accurately detect and alleviate symptoms of delirium in persons with dementia, thanks to a five-year, $2.7-million grant from the National Institute of Nursing Research.The project, led by Donna Fick, professor of nursing, Penn State, seeks to improve nurses' assessment skills and reduce the use of drugs to treat delirium and dementia.

5 Aug 2010

Gene associated with susceptibility to chronic pain caused by nerve injury identified

Researchers at the Hebrew University of Jerusalem and elsewhere have succeeded in identifying for the first time a gene associated with susceptibility to chronic pain caused by nerve injury in humans, signalling a significant step toward better understanding and treating of the condition.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

ARIAD reports $159.3 million second-quarter net income

ARIAD Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010 and provided an update on corporate developments.

5 Aug 2010

Penn. effort fades to override cuts to family planning; Ill. faces budget cuts to health care; Mich. focuses on high cost of chronic disease

The Philadelphia Inquirer: "As two Democratic state lawmakers initiated a campaign to override the governor's veto of $7.5 million for family-planning health centers, six Republican state senators who previously voted to restore the funding reversed course, most likely ending any hopes of restoring the money. Democrats would need at least four Republican votes for an override in the Senate, which now appears unlikely.

5 Aug 2010

Shire proposes acquisition of Movetis for fully diluted equity purchase price of EUR428 million

Shire plc, the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company. Movetis is listed on Euronext and focuses on discovering, developing and commercializing innovative treatments for GI conditions with a high unmet medical need.

5 Aug 2010

Injecting PAP may reduce chronic pain: Research

A study published in the Aug. 4, 2010 issue of the Journal of Neuroscience introduces an enzyme that could pack a big punch in the battle against chronic pain. Its name is prostatic acid phosphatase or PAP for short. According to researchers at the University of North Carolina at Chapel Hill, PAP blocks pain in animal models by siphoning off a molecule called PIP2—a critical component of the chemical cascade behind chronic pain.

5 Aug 2010

DURECT second-quarter net loss decreases to $6.3 million

DURECT Corporation announced today financial results for the three months ended June 30, 2010. Total revenues were $7.3 million for the three months ended June 30, 2010 compared to $4.9 million for the three months ended June 30, 2009. Net loss for the three months ended June 30, 2010 was $6.3 million, compared to a net loss of $7.5 million for the same period in 2009.

5 Aug 2010

EEG patterns can predict schizophrenia patients' response to clozapine therapy

A commonplace electroencephalography (EEG) test may hold the key to predicting whether a person will respond to certain prescribed drugs, particularly those related to psychiatric conditions.In a study to be published by Clinical Neurophysiology, and now posted online, engineering and health sciences researchers at McMaster University applied machine learning to EEG patterns and successfully predicted how patients with schizophrenia would respond to clozapine therapy.

5 Aug 2010

Scientist invents new approach to boost body's response to vaccinations

As the medical community searches for better vaccines and ways to deliver them, a University of Rochester scientist believes he has discovered a new approach to boosting the body's response to vaccinations.Richard P. Phipps, Ph.D., found that the same molecules used in drugs that treat diabetes also stimulate B cells in the immune system, pushing them to make antibodies for protection against invading microorganisms.

5 Aug 2010

Arthritis treatment costs more than $128 billion a year in the U.S.

Arthritis is the single greatest cause of chronic pain and disability among Americans and the treatment of arthritis costs the nation more than $128 billion a year in medical care and lost earnings. Persistent, chronic joint pain determines the choices people make and limits their ability to perform basic tasks for themselves and their family. Eighty percent of Americans either have, or know someone who has, arthritis and these numbers continue to escalate.

4 Aug 2010

Research examines effects of orthostatic hypotension in adults, children

A simple variation to the tried and true method of checking blood pressure can reveal startling information about both older and younger persons, new research suggests.

4 Aug 2010

Chronic News and Research

Researchers identify gene associated with susceptibility to chronic pain caused by nerve injury

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

BioCryst second-quarter total revenues increase to $7.6 million

New studies question wide-spread hypothesis that CCSVI contribute to development of MS

Affymax, Takeda announce preliminary strategy for Hematide to treat anemia in chronic renal failure patients

EBRI publishes detailed summary of consumer-driven health plans

Project for improving nurses' assessment skills to detect and alleviate delirium symptoms

Gene associated with susceptibility to chronic pain caused by nerve injury identified

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

ARIAD reports $159.3 million second-quarter net income

Penn. effort fades to override cuts to family planning; Ill. faces budget cuts to health care; Mich. focuses on high cost of chronic disease

Shire proposes acquisition of Movetis for fully diluted equity purchase price of EUR428 million

Injecting PAP may reduce chronic pain: Research

DURECT second-quarter net loss decreases to $6.3 million

EEG patterns can predict schizophrenia patients' response to clozapine therapy

Scientist invents new approach to boost body's response to vaccinations

Arthritis treatment costs more than $128 billion a year in the U.S.

Research examines effects of orthostatic hypotension in adults, children

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News